Own a piece of the brain health revolution.
U: The Mind Company is building the future of non-invasive brain stimulation — for Parkinson's, Alzheimer's, and everyday cognitive wellness. And you can be part of it.
Why invest in non-invasive brain stimulation?
Massive Market
Parkinson's disease alone costs the US $52 billion annually. Alzheimer's exceeds $300 billion. The brain health and wellness market is projected to reach $11.8 billion by 2030.
Revenue Today
Unlike most medical device startups, U is already generating revenue through NeuroEdge consumer device sales. Projected $830K in FY2026 revenue with a path to cash-positive by August.
Deep IP Moat
5 patents (3 granted, 2 pending) covering the core am-tPCS technology, electrode configurations, and amplitude modulation protocols.
Proven Technology
250+ patients treated. 32,000+ treatment hours. Peer-reviewed publications. Controlled clinical trials in multiple countries. We have real data, not just a concept.
Dual Revenue Model
Consumer (NeuroEdge device + subscription) and clinical (Sphere/Axis licensing) revenue streams. The consumer product funds R&D for clinical devices.
FDA Pathway Clear
Our regulatory team has mapped the FDA De Novo pathways for Sphere (Q241396/S003) and Axis (Q252914/S001), with target submissions in 2027 and expected clearance in 2028. NeuroEdge is selling today as a consumer wellness device.
How we'll use the funds.
Investment Disclaimer: This is not an offer to sell securities. Investing in early-stage companies involves significant risk, including the possible loss of your entire investment. This raise is conducted under Regulation Crowdfunding via WeFunder. Please review the full offering documents, including risk factors, on WeFunder before investing. Forward-looking statements (including revenue projections) are not guarantees of future performance. Past clinical results are not necessarily indicative of future clinical outcomes.
Join the brain health revolution.
Starting at $100. Every investment helps us bring this technology closer to the patients who need it.
Invest on WeFunder →